REGEN-X
Price range: $89.99 through $399.00
Advanced Recovery & Growth Support Matrix
REGEN-X is a premium dual-peptide formulation combining BPC-157 and CJC-1295 DAC, two extensively researched peptides recognized for their complementary roles in recovery, regeneration, and growth hormone support. Designed to combine tissue-focused recovery pathways with sustained growth hormone signaling, REGEN-X™ represents a next-generation approach to performance, recovery, and longevity research.
This innovative peptide complex has gained significant attention in regenerative, metabolic, and performance-focused investigations due to its potential to support recovery processes, tissue maintenance, and physiological adaptation.
SHARE PRODUCT
Payment Support:
Description
Tissue Recovery Support
Investigated for its potential role in tissue repair, regeneration, and recovery-focused research.
Growth Hormone Optimization
Supports research involving natural growth hormone and IGF-1 signaling pathways.
Recovery Enhancement
Studied for its involvement in post-exercise recovery and physical resilience.
Cellular Repair Mechanisms
Research explores its effects on cellular maintenance and regenerative processes.
Performance & Longevity Research
Frequently investigated in studies involving recovery, body composition, and healthy aging.
Quality Assurance
Every batch of REGEN-X undergoes rigorous analytical testing and quality verification to ensure exceptional purity, consistency, and reliability.
Quality Standards
✓ High-Purity Peptide Components
✓ Analytical Quality Verification
✓ Research-Grade Manufacturing
✓ Batch Consistency Testing
✓ Strict Quality Control Procedures
✓ Secure Packaging & Storage
Product Specifications
Product Name: REGEN-X
Blend Composition: BPC-157 + CJC-1295 DAC
Research Category: Recovery & Growth Hormone Research
Format: Lyophilized Peptide Blend
Quality Standard: Research Grade
Additional information
| Variant | 1 Vial, 10 Vials, 5 Vials |
|---|
You must be logged in to post a review.
Reviews
There are no reviews yet.